Changes of serum vascular endothelial growth factor of patients with rectal cancer before and after neoadjuvant chemotherapy and tumor progress.
In the rapid development of armamentarium, neoadjuvant chemotherapy has become an important part of a multi-instrument comprehensive treatment of malignant tumor, which presents promising application prospects. This paper researches changes of Vascular Endothelial Growth Factor (VEGF) and Vascular Endothelial Growth Factor-2 (VEGF-2) in serum of patients with rectal cancer before and after neoadjuvant chemotherapy and discusses how tumor progression rules relate to curative effect and prognosis. Enzyme linked immunosorbent serologic assay (ELISA) was applied for the detection of VEGF expression and VEGF-2 expression of 45 patients with rectal cancer (treatment group) before and after neoadjuvant chemotherapy, which was compared to the expressions of 45 healthy people (control group). After 8 weeks of continuous neoadjuvant chemotherapy, the results did not present obvious differences of VEGF and VEGF-2 expression in patients with different curative effects between pre-chemotherapy and post-chemotherapy. However, VEGF and VEGF-2 expression of patients with CR+PR and NC significantly decreased. This proved the excellent curative effect of neoadjuvant chemotherapy, with which the expressions of VEGF and VEGF-2 of rectal cancer patients decreased. The above experiment provides new ideas for the application of neoadjuvant chemotherapy in treating rectal cancer.